BR9911357A - Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility - Google Patents
Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragilityInfo
- Publication number
- BR9911357A BR9911357A BR9911357-0A BR9911357A BR9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A
- Authority
- BR
- Brazil
- Prior art keywords
- fragility
- ghs
- serm
- modulators
- selective
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 2
- 108010038795 estrogen receptors Proteins 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- -1 4- (2-pyrrolidin-1-yl-ethoxy) -phenyl Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Patente de Invenção: <B>"COMBINAçõES TERAPêUTICAS DE MODULADORES (SELETIVOS) DE RECEPTOR DE ESTROGêNIO (SERM) E SECRETAGOGOS DE HORMÈNIO DE CRESCIMENTO (GHS) PARA TRATAR FRAGILIDADE MúSCULO-ESQUELETAL"<D>. Esta invenção refere-se a combinações de composições farmacêuticas e a métodos que contenham (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etóxi)-fenil)-5,6,7,8-tetrehidronaftale n-2-ol ou um seu sal farmaceuticamente aceitável e 2-amino-N-(1(R)-(2,4-difluoro-benziloximetil)-2-oxo-2-(3-oso-3a (R)-piridin-2-ilmetil)-2-(2,2,2-trifluoro-etil)-2,3,3a,4,6,7-hexahidro-piraz olo [4,3,-c] piridin-5-il)-etil)-2-metil-propionamida ou um seu sal farmaceuticamente aceitável, métodos para a utilização de tais composições e kits que contenham tais composições. As composições são úteis para o tratamento de fragilidade musculo-esqueletal, incluindo a osteoporose, a fratura osteoporótica, a fraca massa óssea, a fragilidade e a fraca massa muscular.Patent of Invention: <B> "THERAPEUTIC COMBINATIONS OF MODULATORS (SELECTIVE) OF ESTROGEN RECEPTOR (SERM) AND SECRETAGOGRAPHY OF GROWTH HORMONE (GHS) TO TREAT MUSCLE-SKELETAL FRAGILITY" <D>. This invention relates to combinations of pharmaceutical compositions and to methods containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7 , 8-tetrehydronaftale n-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N- (1 (R) - (2,4-difluoro-benzyloxymethyl) -2-oxo-2- (3-oso-3a (R) -pyridin-2-ylmethyl) -2- (2,2,2-trifluoro-ethyl) -2,3,3a, 4,6,7-hexahydro-pyrazole [4,3, -c] pyridin -5-yl) -ethyl) -2-methyl-propionamide or a pharmaceutically acceptable salt thereof, methods for using such compositions and kits containing such compositions. The compositions are useful for the treatment of musculoskeletal fragility, including osteoporosis, osteoporotic fracture, weak bone mass, fragility and weak muscle mass.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/000796 WO1999065488A1 (en) | 1998-06-16 | 1999-05-03 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9911357A true BR9911357A (en) | 2001-03-13 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9911357-0A BR9911357A (en) | 1998-06-16 | 1999-05-03 | Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (en) |
| JP (1) | JP2002518328A (en) |
| KR (1) | KR20010052817A (en) |
| CN (1) | CN1305378A (en) |
| AP (1) | AP9901581A0 (en) |
| AR (1) | AR018868A1 (en) |
| AU (1) | AU3342099A (en) |
| BG (1) | BG105128A (en) |
| BR (1) | BR9911357A (en) |
| CA (1) | CA2335112A1 (en) |
| CO (1) | CO5070586A1 (en) |
| EA (1) | EA200001189A1 (en) |
| GT (1) | GT199900083A (en) |
| HR (1) | HRP20000857A2 (en) |
| HU (1) | HUP0102395A2 (en) |
| ID (1) | ID26726A (en) |
| IL (1) | IL139587A0 (en) |
| IS (1) | IS5727A (en) |
| MA (1) | MA26648A1 (en) |
| NO (1) | NO20006381L (en) |
| OA (1) | OA11569A (en) |
| PA (1) | PA8472101A1 (en) |
| PE (1) | PE20000633A1 (en) |
| PL (1) | PL345064A1 (en) |
| SK (1) | SK18902000A3 (en) |
| TN (1) | TNSN99118A1 (en) |
| UY (1) | UY25557A1 (en) |
| WO (1) | WO1999065488A1 (en) |
| ZA (1) | ZA993973B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| JP2004507502A (en) * | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | Sustained release formulation for growth hormone secretagogue |
| EP1666033B1 (en) * | 2001-11-29 | 2008-12-31 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| ES2604943T3 (en) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Ghrelin receptor macrocyclic modulators and procedures for their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-05-03 EA EA200001189A patent/EA200001189A1/en unknown
- 1999-05-03 ID IDW20002604A patent/ID26726A/en unknown
- 1999-05-03 CN CN99807381A patent/CN1305378A/en active Pending
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/en not_active Ceased
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Ceased
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/en not_active Application Discontinuation
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/en unknown
- 1999-05-03 HR HR20000857A patent/HRP20000857A2/en not_active Application Discontinuation
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/en unknown
- 1999-05-03 PL PL99345064A patent/PL345064A1/en unknown
- 1999-05-03 IL IL13958799A patent/IL139587A0/en unknown
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/en active Pending
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/en unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/en not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/en not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/en unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/en not_active Application Discontinuation
- 1999-06-15 MA MA25622A patent/MA26648A1/en unknown
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/en unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/en unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/en unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/en unknown
- 2000-12-14 NO NO20006381A patent/NO20006381L/en not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID26726A (en) | 2001-02-01 |
| SK18902000A3 (en) | 2001-12-03 |
| HRP20000857A2 (en) | 2001-10-31 |
| IL139587A0 (en) | 2002-02-10 |
| JP2002518328A (en) | 2002-06-25 |
| PL345064A1 (en) | 2001-11-19 |
| KR20010052817A (en) | 2001-06-25 |
| NO20006381D0 (en) | 2000-12-14 |
| AR018868A1 (en) | 2001-12-12 |
| UY25557A1 (en) | 2001-01-31 |
| HUP0102395A2 (en) | 2001-11-28 |
| GT199900083A (en) | 2000-12-05 |
| EA200001189A1 (en) | 2001-06-25 |
| NO20006381L (en) | 2000-12-14 |
| BG105128A (en) | 2001-11-30 |
| IS5727A (en) | 2000-11-24 |
| PA8472101A1 (en) | 2000-09-29 |
| CO5070586A1 (en) | 2001-08-28 |
| AP9901581A0 (en) | 1999-06-30 |
| PE20000633A1 (en) | 2000-07-26 |
| CN1305378A (en) | 2001-07-25 |
| WO1999065488A1 (en) | 1999-12-23 |
| EP1085867A1 (en) | 2001-03-28 |
| AU3342099A (en) | 2000-01-05 |
| TNSN99118A1 (en) | 2005-11-10 |
| CA2335112A1 (en) | 1999-12-23 |
| OA11569A (en) | 2004-07-01 |
| MA26648A1 (en) | 2004-12-20 |
| ZA993973B (en) | 2000-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309875A (en) | methods and compositions for treating peripheral nervous system disorders and novel compounds useful therefor | |
| EA200400735A1 (en) | 3-β-D-RIBOFURANOSYLTIAZOLO [4,5-d] Pyrimidine Nucleoside and Their Uses | |
| EE04018B1 (en) | Thieno [2,3-d] pyrimidinediones, process for their preparation and pharmaceutical compositions containing them | |
| WO2000021926A3 (en) | 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS | |
| BR9813028A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| ATE384068T1 (en) | THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF RHEUMATHOID ARTHRITIS | |
| BR0100558A (en) | Compositions and methods for treating osteoporosis | |
| IS5082A (en) | Pyrrolo [3,4-D] pyrimidinone derivatives and their use as drugs | |
| BR9911357A (en) | Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility | |
| CA2325842A1 (en) | Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof | |
| BR9909958A (en) | Pharmaceutical formulation, respective preparation and use process and method of treatment or prevention of bone disorders | |
| BR9911228A (en) | Therapeutic combinations comprising a selective modulator of an estrogen receptor and parathyroid hormone | |
| BR9911324A (en) | Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility | |
| BRPI0418887A (en) | 3-beta-d-ribofuranosylthiazole [4,5-d] pyrimidine nucleosides and uses thereof | |
| BR0112619A (en) | Compound, process for preparing it, pharmaceutical formulation, use of a compound, methods for treating 5-hydroxytryptamine-mediated disorders, and disorders of the central nervous system and / or overactive bladder or vasospasm or for growth control of tumors | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| TH57984A3 (en) | A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone. | |
| ATE308995T1 (en) | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING RETROVIRAL INFECTIONS | |
| TH48282A (en) | Treatment of diseases of the drug combination of osteoporosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |